(Q39611506)

English

Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study

scientific article published on April 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

0 references

Human T-lymphotropic virus 1

0 references

1 reference

based on heuristic

inferred from title

spastic paraparesis

1 reference

based on heuristic

inferred from title

author name string

Yamasaki K

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kira J

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Koyanagi Y

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kawano Y

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Miyano-Kurosaki N

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Nakamura M

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Baba E

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Suzuki J

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yamamoto A

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yamamoto N

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kobayashi T

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 1997

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Journal of the Neurological Sciences

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

147

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

135-144

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Human T-cell leukaemia virus type I and neurological disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

HTLV-I-associated myelopathy in a Californian: diagnosis by reactivity to a viral recombinant antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Characterization of adherent T cells to human endothelial cells in patients with HTLV-I-associated myelopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Anti-viral and immunomodulatory effects of interferon-alpha on cultured lymphocytes from patients with human T lymphotropic virus type I-associated myelopathy (HAM/TSP).

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Increases in helper inducer T cells and activated T cells in HTLV-I-associated myelopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Antibody titers to HTLV-I-p40tax protein and gag-env hybrid protein in HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with increased HTLV-I proviral DNA load

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

In vivo infection of human T-cell leukemia virus type I in non-T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

HTLV-I-associated myelopathy endemic in Texas-born residents and isolation of virus from CSF cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Suppressive effects of interferons on the production and release of human T-lymphotropic virus type-I (HTLV-I).

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Retrovirus-associated myelopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Soluble CD4 and CD8 in the peripheral blood of patients with multiple sclerosis and HTLV-1-associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

The effect of intraventricular interferon on subacute sclerosing panencephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0022-510X(96)05319-1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39611506&oldid=1845409200"